FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: implications for combination therapies and early response prediction
This study investigates the impact of FOLFIRINOX on plasma proteins and peripheral immune cells to guide immune-based combination therapies and, ideally, to identify a potential biomarker to predict early disease progression during FOLFIRINOX. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 16, 2023 Category: Cancer & Oncology Authors: Casper W.F. van Eijck, Gaby Strijk, Eveline E. Vietsch, Fleur van der Sijde, Maaike Verheij, Dana Mustafa, Madelief Vink, Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen Tags: Original Research Source Type: research
Lineage-Specific Regulation of PD-1 Expression in Early-Stage Hepatocellular Carcinoma Following 90Yttrium Transarterial Radioembolization – Implications in Treatment Outcomes
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in the world. Liver-directed therapies, including 90Yttrium (90Y) radioembolization, play an integral role in the management of HCC with excellent response rates. This has led to clinical trials of immunotherapy in combination with 90Y. Elevated PD-1 expression and lymphopenia were recently shown as risk factors for disease progression in early-stage HCC treated with liver-directed therapies. The aim of this study was to investigate PD-1 expression dynamics in bridge/downstage to transplant in HCC patients receiving first-cycle 90Y an...
Source: European Journal of Cancer - November 16, 2023 Category: Cancer & Oncology Authors: Kelley G. N úñez, Tyler Sandow, Juan Gimenez, Mina Hibino, Daniel Fort, Ari J. Cohen, Paul T. Thevenot Tags: Original Research Source Type: research
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Accumulation of the HIF-2 α transcription factor is an oncogenic event implicated in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). In the phase I LITESPARK-001 study, the first-in-class HIF-2α inhibitor belzutifan demonstrated antitumor activity and an acceptable safety profile for pretreated patients with advanced ccRCC. Updated data with additional follow-up of>40 months are presented. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 14, 2023 Category: Cancer & Oncology Authors: Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri Tags: Original Research Source Type: research
Clinical Trials That Leverage External Data: Do We Need More Transparent Protocols and Statistical Plans?
Oncology is experiencing a growing interest in the use of external control (EC) data for the design and analysis of clinical trials [2,6]. Data from EC patients may be used in a variety of tasks, for example for the analysis of single arm studies [4] or for early futility stopping of randomized trials [9]. The rationale for incorporating EC data into clinical trials is typically to increase the efficiency of the drug development process. For example, consider newly diagnosed glioblastoma (GBM) patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 14, 2023 Category: Cancer & Oncology Authors: Daniel Evan Schwartz, Hanna Essaouabi, Lorenzo Trippa Tags: Letter to the Editor Source Type: research
Deep learning based histological classification of adnex tumors
Cutaneous adnexal tumors are a diverse group of tumors arising from structures of the hair appendages. Although often benign, malignant entities occur which can metastasize and lead to patients ´ death. Correct diagnosis is critical to ensure optimal treatment and best possible patient outcome. Artificial intelligence (AI) in the form of deep neural networks has recently shown enormous potential in the field of medicine including pathology, where we and others have found common cutaneous tumors can be detected with high sensitivity and specificity. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 14, 2023 Category: Cancer & Oncology Authors: Philipp Jansen, Jean Le ’Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Jörg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank Tags: Original Research Source Type: research
Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (selly)
To evaluate the sensitivity and specificity of sentinel-lymph-node mapping compared with the gold standard of systematic lymphadenectomy in detecting lymph node metastasis in apparent early stage ovarian cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 14, 2023 Category: Cancer & Oncology Authors: Camilla Nero, Nicol ò Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, G Tags: Clinical Trial Source Type: research
Treatment and outcomes in breast cancer patients: a cross section study from the EUSOMA Breast Centre Network
The present study was designed to describe tumour features and treatments for patients with breast cancer. It also aimed at assessing the risk of distant metastases in relation to biological profiles, disease stages and treatment. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 14, 2023 Category: Cancer & Oncology Authors: Cynthia Aristei, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Maria Joao Cardoso, Kwok Leung Cheung, Giuseppe Curigliano, Jakob De Vries, Donatella Santini, Francesco Sardanelli, Peter Van Dam, Isabel Teresa Rubio, EUSOMA Working group Tags: Original Research Source Type: research
Efficacy and Safety of Ripretinib vs. Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor Previously Treated with Imatinib: A Phase 2, Multicenter, Randomized, Open-Label Study in China
A bridging study of INTRIGUE study to assess the efficacy and safety of ripretinib versus sunitinib as second-line treatment in Chinese GIST patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 14, 2023 Category: Cancer & Oncology Authors: Jian Li, Jun Zhang, Yanqiao Zhang, Haibo Qiu, Yanbing Zhou, Yongjian Zhou, Xinhua Zhang, Ye Zhou, Yuping Zhu, Yong Li, Ming Wang, Kuntang Shen, Kaixiong Tao, Xin Wu, Haijiang Wang, Bo Zhang, Jiayu Ling, Yingjiang Ye, Xingye Wu, Hongyan Qu, Yue Ma, Xuelong Tags: Original Research Source Type: research
A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma
This study is the largest prospective cohort of SCNSL patients providing a comprehensive overview of an international real-world treatment landscape and outcomes. Prognosis was better in patients with SCNSL involvement at initial diagnosis (cohort I) and consolidating HDT-ASCT was associated with favorable outcome in patients with PR or better. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 13, 2023 Category: Cancer & Oncology Authors: Stefan Habringer, Uta M. Demel, Anne-Katrin Fietz, Felicitas Lammer, Roland Schroers, Silvia Hofer, Osnat Bairey, Jan Braess, Anna Sofia Meier-Stiegen, Reingard Stuhlmann, Martin Schmidt-Hieber, Johannes Hoffmann, Bettina Zinngrebe, Ulrich Kaiser, Peter R Tags: Original Research Source Type: research
Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial
To the editor: Hand-foot skin reaction (HFSR), characterized by skin abnormalities on palmoplantar surfaces, has an overall incidence of about 35% upon vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) treatment.1 Zinc, which plays a role in maintaining skin health, may be implicated in the pathogenesis of HFSR.2 Zinc deficiency has been shown to associate with dermatological toxicities of epidermal growth factor receptor (EGFR)-TKI.3, 4 Regorafenib, an oral multi-kinase inhibitor targeting VEGFR 1 –3, PDGFR, cKIT, BRAF, and RET1, is approved for the treatment of metastatic colorectal ca...
Source: European Journal of Cancer - November 13, 2023 Category: Cancer & Oncology Authors: Wen-Kuan Huang, Hung-Chih Hsu, Tsai-Sheng Yang, Chun-Wei Lu, Yi-Ru Pan, Chiao-En Wu, Wen-Hung Chung, Shuen-Iu Hung, Chun-Nan Yeh Tags: Current Perspective Source Type: research
Impact of colorectal cancer screening on survival after metachronous metastasis
An increasing proportion of colorectal cancer (CRC) cases in Europe are detected by screening with faecal immunochemical testing (FIT). Previous studies showed that population screening with FIT leads to a decrease in CRC incidence and to detection at an earlier stage. However, approximately twenty percent of patients with CRC without metastases at initial diagnosis still develop metachronous metastases. We investigated the association between detection mode of the primary tumor and overall survival (OS) after metachronous metastasis in patients with CRC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 12, 2023 Category: Cancer & Oncology Authors: Patricia A.H. Hamers, Geraldine R. Vink, Marloes A.G. Elferink, Leon M.G. Moons, Cornelis J.A. Punt, Anne M. May, Miriam Koopman Tags: Original Research Source Type: research
Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-Medicare study
This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with ATAX compared to taxane-based chemotherapy (TAX). (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 11, 2023 Category: Cancer & Oncology Authors: Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond Tags: Original Research Source Type: research
Osimertinib-induced Urticarial Vasculitis in a Patient with Lung Cancer: A Rare Cutaneous Toxicity
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 11, 2023 Category: Cancer & Oncology Authors: Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng Tags: Letter to the Editor Source Type: research
Immunotherapy Response in Microsatellite Stable Metastatic Colorectal Cancer Is Influenced by Site of Metastases
This study explores the impact of metastatic sites on treatment outcomes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 10, 2023 Category: Cancer & Oncology Authors: Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li Tags: Original Research Source Type: research
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: a matching-adjusted indirect comparison
No head-to-head trials compared the efficacy of transarterial radioembolization (TARE, also known as selective internal radiation therapy) to combination immunotherapy in hepatocellular carcinoma (HCC). The analysis objective was to compare effectiveness outcomes of TARE using Y-90 resin microspheres and atezolizumab-bevacizumab (AB) in advanced unresectable HCC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 10, 2023 Category: Cancer & Oncology Authors: Ion Agirrezabal, Mohamed Bouattour, David J Pinato, Antonio D'Alessio, Victoria K Brennan, Phuong Lien Carion, Suki Shergill, Nathalie Amoury, Val érie Vilgrain Tags: Original Research Source Type: research
